RCMI Coordinating Center (RCMI CC) Header Logo

Connection

David Calhoun to Middle Aged

This is a "connection" page, showing publications David Calhoun has written about Middle Aged.
Connection Strength

2.462
  1. Siddiqui M, Judd EK, Zhang B, Dudenbostel T, Carey RM, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. Hypertension. 2021 02; 77(2):435-444.
    View in: PubMed
    Score: 0.073
  2. Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. Am J Hypertens. 2020 08 04; 33(8):741-747.
    View in: PubMed
    Score: 0.071
  3. Siddiqui M, Judd EK, Dudenbostel T, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension. Hypertension. 2020 02; 75(2):510-515.
    View in: PubMed
    Score: 0.068
  4. Siddiqui M, Judd EK, Dudenbostel T, Zhang B, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA. Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. Hypertension. 2019 09; 74(3):652-659.
    View in: PubMed
    Score: 0.066
  5. Siddiqui M, Judd EK, Jaeger BC, Bhatt H, Dudenbostel T, Zhang B, Edwards LJ, Oparil S, Calhoun DA. Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension. Hypertension. 2019 01; 73(1):132-141.
    View in: PubMed
    Score: 0.064
  6. Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG, Oparil S, Calhoun DA. Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018 08; 72(2):343-349.
    View in: PubMed
    Score: 0.061
  7. Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-Coat Effect Is Uncommon in Patients With Refractory Hypertension. Hypertension. 2017 09; 70(3):645-651.
    View in: PubMed
    Score: 0.058
  8. Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension. Am J Hypertens. 2017 May 01; 30(5):518-523.
    View in: PubMed
    Score: 0.057
  9. Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension. 2016 10; 68(4):995-1003.
    View in: PubMed
    Score: 0.054
  10. Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. J Hypertens. 2016 May; 34(5):1005-10.
    View in: PubMed
    Score: 0.053
  11. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens. 2016 06; 10(6):493-9.
    View in: PubMed
    Score: 0.053
  12. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. Hypertension. 2015 Jul; 66(1):126-33.
    View in: PubMed
    Score: 0.050
  13. Breaux-Shropshire TL, Whitt L, Oster RA, Lewis D, Shropshire TS, Calhoun DA. Results of an Academic, Health Care Worksite Weight Loss Contest for Southeastern Americans: Scale Back Alabama 2011-2013. Workplace Health Saf. 2015 Apr; 63(4):165-9.
    View in: PubMed
    Score: 0.049
  14. Breaux-Shropshire TL, Whitt L, Griffin RL, Shropshire AT, Calhoun DA. Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. Workplace Health Saf. 2014 Jul; 62(7):292-300.
    View in: PubMed
    Score: 0.047
  15. Irvin MR, Booth JN, Shimbo D, Lackland DT, Oparil S, Howard G, Safford MM, Muntner P, Calhoun DA. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014 Jun; 8(6):405-13.
    View in: PubMed
    Score: 0.046
  16. Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4):691-7.
    View in: PubMed
    Score: 0.044
  17. Calhoun DA, Lacourci?re Y, Crikelair N, Jia Y, Glazer RD. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Curr Med Res Opin. 2013 Aug; 29(8):901-10.
    View in: PubMed
    Score: 0.044
  18. Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013 Apr; 143(4):978-983.
    View in: PubMed
    Score: 0.043
  19. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield SS, Oparil S, Calhoun DA. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012 Jan; 14(1):7-12.
    View in: PubMed
    Score: 0.039
  20. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, M?nard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011 Nov 01; 124(18):1945-55.
    View in: PubMed
    Score: 0.039
  21. Pisoni R, Acelajado MC, Cartmill FR, Dudenbostel T, Dell'Italia LJ, Cofield SS, Oparil S, Calhoun DA. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens. 2012 Aug; 26(8):502-6.
    View in: PubMed
    Score: 0.038
  22. Lacourci?re Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011 Oct; 25(10):615-22.
    View in: PubMed
    Score: 0.037
  23. Gonzaga CC, Gaddam KK, Ahmed MI, Pimenta E, Thomas SJ, Harding SM, Oparil S, Cofield SS, Calhoun DA. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J Clin Sleep Med. 2010 Aug 15; 6(4):363-8.
    View in: PubMed
    Score: 0.036
  24. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010 May; 55(5):1137-42.
    View in: PubMed
    Score: 0.035
  25. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010 Aug; 24(8):532-7.
    View in: PubMed
    Score: 0.034
  26. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep; 54(3):475-81.
    View in: PubMed
    Score: 0.033
  27. Calhoun DA, Lacourci?re Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 Jul; 54(1):32-9.
    View in: PubMed
    Score: 0.033
  28. Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin. 2008 Aug; 24(8):2303-11.
    View in: PubMed
    Score: 0.031
  29. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008 Jun 09; 168(11):1159-64.
    View in: PubMed
    Score: 0.031
  30. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008 Feb; 51(2):339-44.
    View in: PubMed
    Score: 0.030
  31. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens. 2007 Oct; 25(10):2131-7.
    View in: PubMed
    Score: 0.029
  32. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007 Feb; 131(2):453-9.
    View in: PubMed
    Score: 0.028
  33. Nishizaka MK, Calhoun DA. Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. J Hypertens. 2006 Mar; 24(3):435-6.
    View in: PubMed
    Score: 0.026
  34. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens. 2005 Jun; 18(6):805-12.
    View in: PubMed
    Score: 0.025
  35. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004 Jun 15; 109(23):2857-61.
    View in: PubMed
    Score: 0.023
  36. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004 Mar; 43(3):518-24.
    View in: PubMed
    Score: 0.023
  37. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004 Jan; 125(1):112-7.
    View in: PubMed
    Score: 0.023
  38. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov; 16(11 Pt 1):925-30.
    View in: PubMed
    Score: 0.022
  39. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec; 40(6):892-6.
    View in: PubMed
    Score: 0.021
  40. Kwon Y, Baruch M, Stafford PL, Bonner H, Cho Y, Mazimba S, Logan JG, Shimbo D, Park SH, Lin GM, Azarbarzin A, Calhoun DA, Berry R, Carey RM. Elucidation of obstructive sleep apnoea related blood pressure surge using a novel continuous beat-to-beat blood pressure monitoring system. J Hypertens. 2022 03 01; 40(3):520-527.
    View in: PubMed
    Score: 0.020
  41. Butts B, Brown JA, Denney TS, Ballinger S, Lloyd SG, Oparil S, Sanders P, Merriman TR, Gaffo A, Singh J, Kelley EE, Calhoun DA, Dell'Italia LJ. Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. Hypertension. 2022 04; 79(4):775-784.
    View in: PubMed
    Score: 0.020
  42. Cai A, Liu L, Siddiqui M, Zhou D, Chen J, Calhoun DA, Tang S, Zhou Y, Feng Y. Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes. Am J Hypertens. 2021 02 18; 34(1):64-72.
    View in: PubMed
    Score: 0.019
  43. Thomas SJ, Johnson DA, Guo N, Abdalla M, Booth JN, Spruill TM, Jackson CL, Yano Y, Sims M, Calhoun D, Muntner P, Redline S. Association of Obstructive Sleep Apnea With Nighttime Blood Pressure in African Americans: The Jackson Heart Study. Am J Hypertens. 2020 10 21; 33(10):949-957.
    View in: PubMed
    Score: 0.018
  44. Langford AT, Akinyelure OP, Moore TL, Howard G, Min YI, Hillegass WB, Bress AP, Tajeu GS, Butler M, Jaeger BC, Yano Y, Shimbo D, Ogedegbe G, Calhoun D, Booth JN, Muntner P. Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension: JHS and the REGARDS Study. Hypertension. 2020 11; 76(5):1600-1607.
    View in: PubMed
    Score: 0.018
  45. Siddiqui M, Dominiczak AF, Touyz RM, Carey RM, Basile J, Heslin MJ, Winokur T, Calhoun DA, Oparil S, Dudenbostel T. Case of Episodic and Positional Hypertension: Diagnosis and Treatment. Hypertension. 2020 09; 76(3):614-621.
    View in: PubMed
    Score: 0.018
  46. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020 07 07; 173(1):10-20.
    View in: PubMed
    Score: 0.018
  47. Thomas SJ, Booth JN, Jaeger BC, Hubbard D, Sakhuja S, Abdalla M, Lloyd-Jones DM, Buysse DJ, Lewis CE, Shikany JM, Schwartz JE, Shimbo D, Calhoun D, Muntner P, Carnethon MR. Association of Sleep Characteristics With Nocturnal Hypertension and Nondipping Blood Pressure in the CARDIA Study. J Am Heart Assoc. 2020 04 07; 9(7):e015062.
    View in: PubMed
    Score: 0.017
  48. Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens. 2019 09; 37(9):1797-1804.
    View in: PubMed
    Score: 0.017
  49. Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Cambriles TD, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Olmos LF, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study. Hypertens Res. 2019 11; 42(11):1708-1715.
    View in: PubMed
    Score: 0.016
  50. Navarro-Soriano C, Mart?nez-Garc?a MA, Torres G, Barb? F, Caballero-Eraso C, Lloberes P, Diaz Cambriles T, Somoza M, Masa JF, Gonz?lez M, Ma?as E, de la Pe?a M, Garc?a-R?o F, Montserrat JM, Muriel A, Oscullo G, Feced Olmos L, Garc?a-Ortega A, Calhoun D, Campos-Rodriguez F. Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial. J Hypertens. 2019 06; 37(6):1269-1275.
    View in: PubMed
    Score: 0.016
  51. Johnson DA, Thomas SJ, Abdalla M, Guo N, Yano Y, Rueschman M, Tanner RM, Mittleman MA, Calhoun DA, Wilson JG, Muntner P, Redline S. Association Between Sleep Apnea and Blood Pressure Control Among Blacks. Circulation. 2019 03 05; 139(10):1275-1284.
    View in: PubMed
    Score: 0.016
  52. Booth JN, Allen NB, Calhoun D, Carson AP, Deng L, Goff DC, Redden DT, Reis JP, Shimbo D, Shikany JM, Sidney S, Spring B, Lewis CE, Muntner P. Racial Differences in Maintaining Optimal Health Behaviors Into Middle Age. Am J Prev Med. 2019 03; 56(3):368-375.
    View in: PubMed
    Score: 0.016
  53. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019 02; 73(2):424-431.
    View in: PubMed
    Score: 0.016
  54. Butts B, Calhoun DA, Denney TS, Lloyd SG, Gupta H, Gaddam KK, Aban I, Oparil S, Sanders PW, Patel R, Collawn JF, Dell'Italia LJ. Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. Free Radic Biol Med. 2019 04; 134:343-349.
    View in: PubMed
    Score: 0.016
  55. Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM. Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. Am J Med. 2018 12; 131(12):1463-1472.e7.
    View in: PubMed
    Score: 0.016
  56. Thomas SJ, Booth JN, Dai C, Li X, Allen N, Calhoun D, Carson AP, Gidding S, Lewis CE, Shikany JM, Shimbo D, Sidney S, Muntner P. Cumulative Incidence of Hypertension by 55?Years of Age in Blacks and Whites: The CARDIA Study. J Am Heart Assoc. 2018 07 11; 7(14).
    View in: PubMed
    Score: 0.015
  57. Irvin MR, Booth JN, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P. The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study. J Clin Hypertens (Greenwich). 2018 03; 20(3):438-446.
    View in: PubMed
    Score: 0.015
  58. Flack JM, Calhoun D, Schiffrin EL. The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Hypertens. 2018 01 12; 31(2):133-135.
    View in: PubMed
    Score: 0.015
  59. Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope LM, Dudenbostel T, de la Sierra A. Prevalence and Clinical Characteristics of Refractory Hypertension. J Am Heart Assoc. 2017 Dec 07; 6(12).
    View in: PubMed
    Score: 0.015
  60. Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO. Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number. Am J Hypertens. 2017 Nov 01; 30(11):1112-1119.
    View in: PubMed
    Score: 0.015
  61. Calhoun DA, Oparil S. High blood pressure in women. Int J Fertil Womens Med. 1997 May-Jun; 42(3):198-205.
    View in: PubMed
    Score: 0.014
  62. Wolley MJ, Pimenta E, Calhoun D, Gordon RD, Cowley D, Stowasser M. Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea. J Hum Hypertens. 2017 09; 31(9):561-567.
    View in: PubMed
    Score: 0.014
  63. Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension. 2017 05; 69(5):827-835.
    View in: PubMed
    Score: 0.014
  64. Thomas SJ, Booth JN, Bromfield SG, Seals SR, Spruill TM, Ogedegbe G, Kidambi S, Shimbo D, Calhoun D, Muntner P. Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study. J Am Soc Hypertens. 2017 Apr; 11(4):204-212.e5.
    View in: PubMed
    Score: 0.014
  65. Bhandari SK, Shi J, Molnar MZ, Rasgon SA, Derose SF, Kovesdy CP, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ. Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. Respirology. 2016 11; 21(8):1486-1492.
    View in: PubMed
    Score: 0.013
  66. Corr?a NB, de Faria AP, Ritter AM, Sabbatini AR, Almeida A, Brunelli V, Calhoun DA, Moreno H, Modolo R. A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. J Am Soc Hypertens. 2016 06; 10(6):510-516.e1.
    View in: PubMed
    Score: 0.013
  67. Schiffrin EL, Calhoun DA, Flack JM. SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. Am J Hypertens. 2016 Jan; 29(1):2-4.
    View in: PubMed
    Score: 0.013
  68. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015 Sep; 88(3):622-32.
    View in: PubMed
    Score: 0.012
  69. Yano Y, Ning H, Muntner P, Reis JP, Calhoun DA, Viera AJ, Levine DA, Jacobs DR, Shimbo D, Liu K, Greenland P, Lloyd-Jones D. Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Hypertens. 2015 Oct; 28(10):1240-7.
    View in: PubMed
    Score: 0.012
  70. Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, Oparil S, Muntner P. Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. Am J Med. 2015 Jul; 128(7):707-14.e2.
    View in: PubMed
    Score: 0.012
  71. Calhoun DA, Mutinga ML, Wyss JM, Oparil S. Muscle sympathetic nervous system activity in black and Caucasian hypertensive subjects. J Hypertens. 1994 Nov; 12(11):1291-6.
    View in: PubMed
    Score: 0.012
  72. Schiros CG, Desai RV, Venkatesh BA, Gaddam KK, Agarwal S, Lloyd SG, Calhoun DA, Denney TS, Dell'italia LJ, Gupta H. Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson. 2014 Sep 26; 16:70.
    View in: PubMed
    Score: 0.012
  73. Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015 Apr; 29(4):241-6.
    View in: PubMed
    Score: 0.012
  74. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasinh S. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014 Nov; 8(11):808-19.
    View in: PubMed
    Score: 0.012
  75. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014 Nov; 64(5):1012-21.
    View in: PubMed
    Score: 0.012
  76. Modolo R, de Faria AP, Paganelli MO, Sabbatini AR, Barbaro NR, Nascimento BB, Ramos CD, Fontana V, Calhoun DA, Moreno H. Predictors of silent myocardial ischemia in resistant hypertensive patients. Am J Hypertens. 2015 Feb; 28(2):200-7.
    View in: PubMed
    Score: 0.012
  77. White WB, Turner JR, Sica DA, Bisognano JD, Calhoun DA, Townsend RR, Aronow HD, Bhatt DL, Bakris GL. Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014 Oct; 8(10):743-57.
    View in: PubMed
    Score: 0.012
  78. Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, Jiang HH, Threlkeld RJ, Robertson KE, Geiger MJ. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014 Oct; 64(4):731-7.
    View in: PubMed
    Score: 0.012
  79. de la Sierra A, Calhoun DA, Vinyoles E, Banegas JR, de la Cruz JJ, Gorostidi M, Segura J, Ruilope LM. Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. J Hum Hypertens. 2014 Jul; 28(7):416-20.
    View in: PubMed
    Score: 0.011
  80. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock DG, Muntner P. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis. 2014 May; 63(5):781-8.
    View in: PubMed
    Score: 0.011
  81. Santos RC, de Faria AP, Barbaro NR, Modolo R, Ferreira-Melo SE, Matos-Souza JR, Coelho OR, Yugar-Toledo JC, Fontana V, Calhoun D, Moreno H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014 Feb; 70(2):147-54.
    View in: PubMed
    Score: 0.011
  82. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti?rrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013 Sep; 8(9):1583-90.
    View in: PubMed
    Score: 0.011
  83. Eirin A, Zhu XY, Woollard JR, Herrmann SM, Gloviczki ML, Saad A, Juncos LA, Calhoun DA, Rule AD, Lerman A, Textor SC, Lerman LO. Increased circulating inflammatory endothelial cells in blacks with essential hypertension. Hypertension. 2013 Sep; 62(3):585-91.
    View in: PubMed
    Score: 0.011
  84. Shimbo D, Levitan EB, Booth JN, Calhoun DA, Judd SE, Lackland DT, Safford MM, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013 Feb; 31(2):370-6.
    View in: PubMed
    Score: 0.011
  85. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012 May; 59(5):926-33.
    View in: PubMed
    Score: 0.010
  86. Ahmed MI, Desai RV, Gaddam KK, Venkatesh BA, Agarwal S, Inusah S, Lloyd SG, Denney TS, Calhoun D, Dell'italia LJ, Gupta H. Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging. 2012 Mar; 5(3):273-81.
    View in: PubMed
    Score: 0.010
  87. Textor SC, Gloviczki ML, Flessner MF, Calhoun DA, Glockner J, Grande JP, McKusick MA, Cha SS, Lerman LO. Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. Am J Kidney Dis. 2012 Feb; 59(2):229-37.
    View in: PubMed
    Score: 0.010
  88. Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J Am Soc Hypertens. 2012 Jan-Feb; 6(1):66-72.
    View in: PubMed
    Score: 0.010
  89. Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF. Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population. J Hypertens. 2011 Aug; 29(8):1553-9.
    View in: PubMed
    Score: 0.010
  90. Quinaglia T, Martins LC, Figueiredo VN, Santos RC, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension. J Hum Hypertens. 2011 Nov; 25(11):656-64.
    View in: PubMed
    Score: 0.009
  91. Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, J?nior HM. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. DNA Cell Biol. 2011 Aug; 30(8):555-64.
    View in: PubMed
    Score: 0.009
  92. Levine DA, Calhoun DA, Prineas RJ, Cushman M, Howard VJ, Howard G. Moderate waist circumference and hypertension prevalence: the REGARDS Study. Am J Hypertens. 2011 Apr; 24(4):482-8.
    View in: PubMed
    Score: 0.009
  93. Levine DA, Lewis CE, Williams OD, Safford MM, Liu K, Calhoun DA, Kim Y, Jacobs DR, Kiefe CI. Geographic and demographic variability in 20-year hypertension incidence: the CARDIA study. Hypertension. 2011 Jan; 57(1):39-47.
    View in: PubMed
    Score: 0.009
  94. Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H. Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011 Sep; 25(9):532-8.
    View in: PubMed
    Score: 0.009
  95. Zappe DH, Palmer BF, Calhoun DA, Purkayastha D, Samuel R, Jamerson KA. Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension. J Hum Hypertens. 2010 Jul; 24(7):483-91.
    View in: PubMed
    Score: 0.009
  96. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul; 23(7):479-89.
    View in: PubMed
    Score: 0.008
  97. Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. Hypertension. 2008 Aug; 52(2):279-86.
    View in: PubMed
    Score: 0.008
  98. White WB, Calhoun DA, Samuel R, Taylor AA, Zappe DH, Purkayastha D. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. J Clin Hypertens (Greenwich). 2008 Jun; 10(6):450-8.
    View in: PubMed
    Score: 0.008
  99. Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ. Low birth weight is associated with chronic kidney disease only in men. Kidney Int. 2008 Mar; 73(5):637-42.
    View in: PubMed
    Score: 0.007
  100. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan; 25(1):217-26.
    View in: PubMed
    Score: 0.007
  101. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, McClelland J, Cook J, MacMurdy K, Swenson R, Connor SL, Gerhard G, Kraemer DF, Oseran D, Marchant C, Calhoun D, Shnider R, McAnulty J. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA. 2005 Jun 15; 293(23):2884-91.
    View in: PubMed
    Score: 0.006
  102. Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens. 2005 Jan; 18(1):3-12.
    View in: PubMed
    Score: 0.006
  103. Hicken BL, Calhoun DA, Barton JC, Tucker DC. Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. Genet Test. 2004; 8(2):90-7.
    View in: PubMed
    Score: 0.006
  104. Aqel RA, Zoghbi GJ, Baldwin SA, Auda WS, Calhoun DA, Coffey CS, Perry GJ, Iskandrian AE. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J Hypertens. 2003 Jun; 21(6):1157-62.
    View in: PubMed
    Score: 0.005
  105. Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther. 2001 Aug; 23(8):1166-79.
    View in: PubMed
    Score: 0.005
  106. Payami H, Lee N, Zareparsi S, Gonzales McNeal M, Camicioli R, Bird TD, Sexton G, Gancher S, Kaye J, Calhoun D, Swanson PD, Nutt J. Parkinson's disease, CYP2D6 polymorphism, and age. Neurology. 2001 May 22; 56(10):1363-70.
    View in: PubMed
    Score: 0.005
  107. Sola MC, Juul SE, Meng YG, Garg S, Sims P, Calhoun DA, Dame JB, Christensen D. Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c-mpl) during human fetal development. Early Hum Dev. 1999 Jan; 53(3):239-50.
    View in: PubMed
    Score: 0.004
  108. Grassi G, Seravalle G, Calhoun DA, Bolla GB, Giannattasio C, Marabini M, Del Bo A, Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation. 1994 Jul; 90(1):248-53.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support